title: Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients.
abstract: The effect of thiamine (vitamin B(1)) or riboflavin (vitamin B(2)) availability on fasting total homocysteine (tHcy) plasma levels in end-stage renal disease patients is unknown. A cross-sectional study was performed in a population of non-vitamin supplemented patients maintained on continuous ambulatory peritoneal dialysis. Red blood cell availability of thiamine (alpha-ETK) and of riboflavin (alpha-EGR), along with other predictors of tHcy plasma levels, was considered in the analysis. There was a linear association of alpha-EGR with tHcy plasma concentrations (P = 0.009), which was not observed for alpha-ETK. Among red blood cell vitamins, alpha-EGR was the only predictor of tHcy levels (P = 0.035), whereas alpha-ETK, red blood cell pyridoxal-5-phosphate supply (alpha-EGOT) and red blood cell folate levels had no effect. The risk for having a high tHcy plasma levels within the fourth quartile (plasma tHcy >38.3 micromol/L) was increased by an alpha-EGR > median (odds ratio, 4.706; 95% confidence interval, 1.124 to 19.704; P = 0.026). By way of contrast, alpha-ETK had no effect in these analyses. Independent predictors of tHcy plasma levels were serum albumin, alpha-EGR, red blood cell folate, and certain MTHFR genotypes. A logistic regression analysis showed that the MTHFR genotype is a predictor for having a tHcy plasma concentration within the fourth quartile. In summary, riboflavin availability, as measured by alpha-EGR, is a determinant of fasting tHcy plasma levels in peritoneal dialysis patients. This finding may have implications for tHcy lowering therapy in individuals with end-stage renal disease.
authors.affiliation: Division of Nephrology and Dialysis, Department of Medicine III, University of Vienna, Vienna, Austria.
authors.forename: Sonja
authors.initials: S
authors.lastname: Skoupy
authors.forename: Manuela
authors.initials: M
authors.lastname: Födinger
authors.forename: Mario
authors.initials: M
authors.lastname: Veitl
authors.forename: Agnes
authors.initials: A
authors.lastname: Perschl
authors.forename: Heidi
authors.initials: H
authors.lastname: Puttinger
authors.forename: Claudia
authors.initials: C
authors.lastname: Röhrer
authors.forename: Karin
authors.initials: K
authors.lastname: Schindler
authors.forename: Andreas
authors.initials: A
authors.lastname: Vychytil
authors.forename: Walter H
authors.initials: WH
authors.lastname: Hörl
authors.forename: Gere
authors.initials: G
authors.lastname: Sunder-Plassmann
mesh_terms: D000704:Analysis of Variance; D016009:Chi-Square Distribution; D018592:Cross-Over Studies; D005260:Female; D005838:Genotype; D006710:Homocysteine / Q000097:blood* / Q000235:genetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000235:genetics / Q000628:therapy; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D012256:Riboflavin / Q000097:blood*; D013831:Thiamine / Q000097:blood
chemical_list: D006710:Homocysteine; D012256:Riboflavin; D013831:Thiamine